Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning

Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis

(2013) Jennifer A. Kanakry et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

(2013) R. B. Walter et al.   BLOOD

T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation

(2013) Asad Bashey et al.   JOURNAL OF CLINICAL ONCOLOGY

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study

(2013) Hui Liu et al.   Journal of Hematology & Oncology

Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide

(2013) C. G. Kanakry et al.   Science Translational Medicine

Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning

(2012) Anna Maria Raiola et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow

(2012) M. Mielcarek et al.   BLOOD

Comparative Outcomes of Donor Graft CD34+Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation

(2012) Marcelo C. Pasquini et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine

(2012) Je-Hwan Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors

(2012) Claudio Anasetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow Transplantation

(2012) Leo Luznik et al.   SEMINARS IN ONCOLOGY

Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life

(2011) Gheath Alatrash et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius

(2011) G. Socie et al.   BLOOD

Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia

(2011) Mitchell E Horwitz   CURRENT OPINION IN ONCOLOGY

The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling

(2010) Benigno C. Valdez et al.   BIOCHEMICAL PHARMACOLOGY

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation

(2010) Steven Z. Pavletic et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation

(2010) Javier Bolaños-Meade et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

(2010) L. Luznik et al.   BLOOD

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts

(2009) Boglarka Gyurkocza et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Rapid Transport and Infusion of Hematopoietic Cells Is Associated with Improved Outcome after Myeloablative Therapy and Unrelated Donor Transplant

(2009) Hillard M. Lazarus et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

(2009) Jürgen Finke et al.   LANCET ONCOLOGY

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

(2009) M Brüggemann et al.   LEUKEMIA

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

(2008) Leo Luznik et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Outcomes following HSCT Using Fludarabine, Busulfan, and Thymoglobulin: A Matched Comparison to Allogeneic Transplants Conditioned with Busulfan and Cyclophosphamide

(2008) Christopher N. Bredeson et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS

(2008) Borje S. Andersson et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen

(2008) J Bolaños-Meade et al.   BONE MARROW TRANSPLANTATION